Uses mass spectrometry-based quantitative proteomics to analyze the proteome in acute myeloid leukemia (AML) patient cells, aiming to unravel more of the complex biological processes behind AML and to find prognostic biomarkers which can guide therapeutic decisions.
Other research interests are cell-cell communication in the AML microenviroment and proteomic method optimization.
- 2017. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
- 2016. Systemic Analysis of Regulated Functional Networks. Methods in molecular biology. 287-310.
- 2016. Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients. Biological Procedures Online. 1-10.
- 2016. Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Proteomics. 1154-1165.
- 2016. Global cell proteome profiling, phospho-signaling and quantitative proteomics for identification of new biomarkers in acute myeloid leukemia patients. Current Pharmaceutical Biotechnology. 52-70.
- 2016. Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows. Journal of Proteomics. 214-225.
- 2015. Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. Proteomics. 3361-3369.
- 2019. An overview on G protein-coupled receptor-induced signal transduction in acute myeloid leukemia. 5293-5316.
- 2018. Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. 13-24.
- 2017. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. 1053-1065.
Acute myeloid leukemia research